| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
6,373 |
5,350 |
$1.36M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
9,574 |
8,381 |
$792K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
5,073 |
1,259 |
$134K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
3,653 |
3,115 |
$121K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
6,677 |
1,455 |
$117K |
| 71046 |
Radiologic examination, chest; 2 views |
1,752 |
1,500 |
$96K |
| A0425 |
Ground mileage, per statute mile |
1,837 |
1,322 |
$92K |
| G0378 |
Hospital observation service, per hour |
222 |
63 |
$88K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
453 |
396 |
$55K |
| 87276 |
|
4,120 |
3,682 |
$53K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
3,781 |
773 |
$51K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
1,080 |
874 |
$51K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,847 |
1,481 |
$48K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
10,716 |
8,211 |
$48K |
| 80053 |
Comprehensive metabolic panel |
8,489 |
6,332 |
$47K |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
20,037 |
5,300 |
$44K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,478 |
1,162 |
$43K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,405 |
1,902 |
$42K |
| 87275 |
|
4,124 |
3,682 |
$42K |
| 36415 |
Collection of venous blood by venipuncture |
20,120 |
15,462 |
$38K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,109 |
1,875 |
$27K |
| 97161 |
|
592 |
469 |
$21K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
651 |
544 |
$18K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
457 |
366 |
$16K |
| 70450 |
Computed tomography, head or brain; without contrast material |
111 |
79 |
$15K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
732 |
602 |
$10K |
| A0427 |
Ambulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) |
910 |
666 |
$10K |
| 84484 |
|
1,639 |
1,240 |
$9K |
| 80050 |
General health panel |
264 |
214 |
$9K |
| 71045 |
Radiologic examination, chest; single view |
394 |
301 |
$8K |
| 82553 |
|
1,715 |
1,280 |
$8K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
68 |
63 |
$8K |
| 87420 |
|
634 |
572 |
$8K |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
2,637 |
1,910 |
$6K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
632 |
547 |
$6K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
116 |
67 |
$6K |
| 81001 |
|
3,208 |
2,604 |
$6K |
| 82550 |
|
1,861 |
1,395 |
$6K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
261 |
187 |
$5K |
| A0428 |
Ambulance service, basic life support, non-emergency transport, (bls) |
70 |
48 |
$5K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
37 |
13 |
$5K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
955 |
819 |
$4K |
| 80306 |
|
359 |
295 |
$4K |
| J3490 |
Unclassified drugs |
853 |
482 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
56 |
39 |
$3K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
388 |
349 |
$3K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
135 |
113 |
$3K |
| 84703 |
|
483 |
423 |
$3K |
| 87486 |
|
92 |
78 |
$3K |
| 87581 |
|
92 |
78 |
$3K |
| 80061 |
Lipid panel |
238 |
211 |
$2K |
| A4216 |
Sterile water, saline and/or dextrose, diluent/flush, 10 ml |
1,867 |
1,282 |
$2K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
106 |
84 |
$2K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
485 |
400 |
$2K |
| 92523 |
|
15 |
14 |
$2K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
16 |
16 |
$2K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
331 |
264 |
$1K |
| 85027 |
|
334 |
284 |
$1K |
| J7131 |
Hypertonic saline solution, 1 ml |
974 |
622 |
$866.94 |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
64 |
38 |
$836.23 |
| 81003 |
|
589 |
498 |
$820.29 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
109 |
92 |
$772.77 |
| 86357 |
|
16 |
16 |
$603.68 |
| 86355 |
|
16 |
16 |
$603.68 |
| 87498 |
|
16 |
16 |
$561.44 |
| 87496 |
|
16 |
16 |
$561.44 |
| 87532 |
|
16 |
16 |
$561.44 |
| 85379 |
|
92 |
78 |
$549.75 |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
159 |
90 |
$498.40 |
| 87040 |
|
55 |
37 |
$491.69 |
| 86140 |
|
146 |
128 |
$463.06 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
89 |
79 |
$455.29 |
| 87503 |
|
16 |
16 |
$452.16 |
| 83690 |
|
70 |
39 |
$348.56 |
| 83655 |
|
27 |
27 |
$326.97 |
| 83735 |
|
75 |
65 |
$303.16 |
| 85610 |
|
116 |
81 |
$271.78 |
| 83605 |
|
45 |
27 |
$256.99 |
| 82077 |
|
33 |
12 |
$256.43 |
| 82150 |
|
55 |
28 |
$229.15 |
| 85730 |
|
68 |
55 |
$189.16 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
15 |
12 |
$120.54 |
| 85651 |
|
12 |
12 |
$42.70 |
| 85018 |
|
18 |
18 |
$42.66 |
| 84436 |
|
15 |
12 |
$19.74 |
| A9270 |
Non-covered item or service |
58 |
38 |
$0.00 |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
246 |
123 |
$0.00 |
| T1015 |
Clinic visit/encounter, all-inclusive |
901 |
363 |
$0.00 |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
110 |
81 |
$0.00 |